#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia Genetic risk for schizophrenia (SCZ) is determined by many genetic loci whose compound biological effects are difficult to determine.
1-1	0-4	DRD2	_
1-2	5-18	co-expression	_
1-3	19-26	network	_
1-4	27-30	and	_
1-5	31-32	a	_
1-6	33-40	related	_
1-7	41-50	polygenic	_
1-8	51-56	index	_
1-9	57-64	predict	_
1-10	65-72	imaging	_
1-11	73-74	,	_
1-12	75-85	behavioral	_
1-13	86-89	and	_
1-14	90-98	clinical	_
1-15	99-109	phenotypes	_
1-16	110-116	linked	_
1-17	117-119	to	_
1-18	120-133	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	134-141	Genetic	_
1-20	142-146	risk	_
1-21	147-150	for	_
1-22	151-164	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	165-166	(	_
1-24	167-170	SCZ	_
1-25	171-172	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-26	173-175	is	_
1-27	176-186	determined	_
1-28	187-189	by	_
1-29	190-194	many	_
1-30	195-202	genetic	_
1-31	203-207	loci	_
1-32	208-213	whose	_
1-33	214-222	compound	_
1-34	223-233	biological	_
1-35	234-241	effects	_
1-36	242-245	are	_
1-37	246-255	difficult	_
1-38	256-258	to	_
1-39	259-268	determine	_
1-40	269-270	.	_

Text=We hypothesized that co-expression pathways of SCZ risk genes are associated with system-level brain function and clinical phenotypes of SCZ.
2-1	271-273	We	_
2-2	274-286	hypothesized	_
2-3	287-291	that	_
2-4	292-305	co-expression	_
2-5	306-314	pathways	_
2-6	315-317	of	_
2-7	318-321	SCZ	_
2-8	322-326	risk	_
2-9	327-332	genes	_
2-10	333-336	are	_
2-11	337-347	associated	_
2-12	348-352	with	_
2-13	353-365	system-level	_
2-14	366-371	brain	_
2-15	372-380	function	_
2-16	381-384	and	_
2-17	385-393	clinical	_
2-18	394-404	phenotypes	_
2-19	405-407	of	_
2-20	408-411	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-21	412-413	.	_

Text=We examined genetic variants related to the dopamine D2 receptor gene DRD2 co-expression pathway and associated them with working memory (WM) behavior, the related brain activity and treatment response.
3-1	414-416	We	_
3-2	417-425	examined	_
3-3	426-433	genetic	_
3-4	434-442	variants	_
3-5	443-450	related	_
3-6	451-453	to	_
3-7	454-457	the	_
3-8	458-466	dopamine	_
3-9	467-469	D2	_
3-10	470-478	receptor	_
3-11	479-483	gene	_
3-12	484-488	DRD2	_
3-13	489-502	co-expression	_
3-14	503-510	pathway	_
3-15	511-514	and	_
3-16	515-525	associated	_
3-17	526-530	them	_
3-18	531-535	with	_
3-19	536-543	working	_
3-20	544-550	memory	_
3-21	551-552	(	_
3-22	553-555	WM	_
3-23	556-557	)	_
3-24	558-566	behavior	_
3-25	567-568	,	_
3-26	569-572	the	_
3-27	573-580	related	_
3-28	581-586	brain	_
3-29	587-595	activity	_
3-30	596-599	and	_
3-31	600-609	treatment	_
3-32	610-618	response	_
3-33	619-620	.	_

Text=Using two independent post-mortem prefrontal messenger RNA (mRNA) data sets (total N=249), we identified a DRD2 co-expression pathway enriched for SCZ risk genes.
4-1	621-626	Using	_
4-2	627-630	two	_
4-3	631-642	independent	_
4-4	643-654	post-mortem	_
4-5	655-665	prefrontal	_
4-6	666-675	messenger	_
4-7	676-679	RNA	_
4-8	680-681	(	_
4-9	682-686	mRNA	_
4-10	687-688	)	_
4-11	689-693	data	_
4-12	694-698	sets	_
4-13	699-700	(	_
4-14	701-706	total	_
4-15	707-712	N=249	_
4-16	713-714	)	_
4-17	715-716	,	_
4-18	717-719	we	_
4-19	720-730	identified	_
4-20	731-732	a	_
4-21	733-737	DRD2	_
4-22	738-751	co-expression	_
4-23	752-759	pathway	_
4-24	760-768	enriched	_
4-25	769-772	for	_
4-26	773-776	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-27	777-781	risk	_
4-28	782-787	genes	_
4-29	788-789	.	_

Text=Next, we identified non-coding single-nucleotide polymorphisms (SNPs) associated with co-expression of this pathway.
5-1	790-794	Next	_
5-2	795-796	,	_
5-3	797-799	we	_
5-4	800-810	identified	_
5-5	811-821	non-coding	_
5-6	822-839	single-nucleotide	_
5-7	840-853	polymorphisms	_
5-8	854-855	(	_
5-9	856-860	SNPs	_
5-10	861-862	)	_
5-11	863-873	associated	_
5-12	874-878	with	_
5-13	879-892	co-expression	_
5-14	893-895	of	_
5-15	896-900	this	_
5-16	901-908	pathway	_
5-17	909-910	.	_

Text=These SNPs were associated with regulatory genetic loci in the dorsolateral prefrontal cortex (P <0.05).
6-1	911-916	These	_
6-2	917-921	SNPs	_
6-3	922-926	were	_
6-4	927-937	associated	_
6-5	938-942	with	_
6-6	943-953	regulatory	_
6-7	954-961	genetic	_
6-8	962-966	loci	_
6-9	967-969	in	_
6-10	970-973	the	_
6-11	974-986	dorsolateral	_
6-12	987-997	prefrontal	_
6-13	998-1004	cortex	_
6-14	1005-1006	(	_
6-15	1007-1008	P	_
6-16	1009-1010	<	_
6-17	1011-1015	0.05	_
6-18	1016-1017	)	_
6-19	1018-1019	.	_

Text=We summarized their compound effect on co-expression into a Polygenic Co-expression Index (PCI), which predicted DRD2 pathway co-expression in both mRNA data sets (all P <0.05).
7-1	1020-1022	We	_
7-2	1023-1033	summarized	_
7-3	1034-1039	their	_
7-4	1040-1048	compound	_
7-5	1049-1055	effect	_
7-6	1056-1058	on	_
7-7	1059-1072	co-expression	_
7-8	1073-1077	into	_
7-9	1078-1079	a	_
7-10	1080-1089	Polygenic	_
7-11	1090-1103	Co-expression	_
7-12	1104-1109	Index	_
7-13	1110-1111	(	_
7-14	1112-1115	PCI	_
7-15	1116-1117	)	_
7-16	1118-1119	,	_
7-17	1120-1125	which	_
7-18	1126-1135	predicted	_
7-19	1136-1140	DRD2	_
7-20	1141-1148	pathway	_
7-21	1149-1162	co-expression	_
7-22	1163-1165	in	_
7-23	1166-1170	both	_
7-24	1171-1175	mRNA	_
7-25	1176-1180	data	_
7-26	1181-1185	sets	_
7-27	1186-1187	(	_
7-28	1188-1191	all	_
7-29	1192-1193	P	_
7-30	1194-1195	<	_
7-31	1196-1200	0.05	_
7-32	1201-1202	)	_
7-33	1203-1204	.	_

Text=We associated the PCI with brain activity during WM performance in two independent samples of healthy individuals (total N=368) and 29 patients with SCZ who performed the n-back task.
8-1	1205-1207	We	_
8-2	1208-1218	associated	_
8-3	1219-1222	the	_
8-4	1223-1226	PCI	_
8-5	1227-1231	with	_
8-6	1232-1237	brain	_
8-7	1238-1246	activity	_
8-8	1247-1253	during	_
8-9	1254-1256	WM	_
8-10	1257-1268	performance	_
8-11	1269-1271	in	_
8-12	1272-1275	two	_
8-13	1276-1287	independent	_
8-14	1288-1295	samples	_
8-15	1296-1298	of	_
8-16	1299-1306	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-17	1307-1318	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-18	1319-1320	(	_
8-19	1321-1326	total	_
8-20	1327-1332	N=368	_
8-21	1333-1334	)	_
8-22	1335-1338	and	_
8-23	1339-1341	29	_
8-24	1342-1350	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-25	1351-1355	with	_
8-26	1356-1359	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-27	1360-1363	who	_
8-28	1364-1373	performed	_
8-29	1374-1377	the	_
8-30	1378-1384	n-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-31	1385-1389	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
8-32	1390-1391	.	_

Text=Greater predicted DRD2 pathway prefrontal co-expression was associated with greater prefrontal activity and longer WM reaction times (all corrected P <0.05), thus indicating inefficient WM processing.
9-1	1392-1399	Greater	_
9-2	1400-1409	predicted	_
9-3	1410-1414	DRD2	_
9-4	1415-1422	pathway	_
9-5	1423-1433	prefrontal	_
9-6	1434-1447	co-expression	_
9-7	1448-1451	was	_
9-8	1452-1462	associated	_
9-9	1463-1467	with	_
9-10	1468-1475	greater	_
9-11	1476-1486	prefrontal	_
9-12	1487-1495	activity	_
9-13	1496-1499	and	_
9-14	1500-1506	longer	_
9-15	1507-1509	WM	_
9-16	1510-1518	reaction	_
9-17	1519-1524	times	_
9-18	1525-1526	(	_
9-19	1527-1530	all	_
9-20	1531-1540	corrected	_
9-21	1541-1542	P	_
9-22	1543-1544	<	_
9-23	1545-1549	0.05	_
9-24	1550-1551	)	_
9-25	1552-1553	,	_
9-26	1554-1558	thus	_
9-27	1559-1569	indicating	_
9-28	1570-1581	inefficient	_
9-29	1582-1584	WM	_
9-30	1585-1595	processing	_
9-31	1596-1597	.	_

Text=Blind prediction of treatment response to antipsychotics in two independent samples of patients with SCZ suggested better clinical course of patientswith greater PCI (total N=87; P <0.05).
10-1	1598-1603	Blind	_
10-2	1604-1614	prediction	_
10-3	1615-1617	of	_
10-4	1618-1627	treatment	_
10-5	1628-1636	response	_
10-6	1637-1639	to	_
10-7	1640-1654	antipsychotics	_
10-8	1655-1657	in	_
10-9	1658-1661	two	_
10-10	1662-1673	independent	_
10-11	1674-1681	samples	_
10-12	1682-1684	of	_
10-13	1685-1693	patients	_
10-14	1694-1698	with	_
10-15	1699-1702	SCZ	_
10-16	1703-1712	suggested	_
10-17	1713-1719	better	_
10-18	1720-1728	clinical	_
10-19	1729-1735	course	_
10-20	1736-1738	of	_
10-21	1739-1751	patientswith	_
10-22	1752-1759	greater	_
10-23	1760-1763	PCI	_
10-24	1764-1765	(	_
10-25	1766-1771	total	_
10-26	1772-1776	N=87	_
10-27	1777-1778	;	_
10-28	1779-1780	P	_
10-29	1781-1782	<	_
10-30	1783-1787	0.05	_
10-31	1788-1789	)	_
10-32	1790-1791	.	_

Text=The findings on this DRD2 co-expression pathway are a proof of concept that gene co-expression can parse SCZ risk genes into biological pathways associated with intermediate phenotypes as well as with clinically meaningful information.
11-1	1792-1795	The	_
11-2	1796-1804	findings	_
11-3	1805-1807	on	_
11-4	1808-1812	this	_
11-5	1813-1817	DRD2	_
11-6	1818-1831	co-expression	_
11-7	1832-1839	pathway	_
11-8	1840-1843	are	_
11-9	1844-1845	a	_
11-10	1846-1851	proof	_
11-11	1852-1854	of	_
11-12	1855-1862	concept	_
11-13	1863-1867	that	_
11-14	1868-1872	gene	_
11-15	1873-1886	co-expression	_
11-16	1887-1890	can	_
11-17	1891-1896	parse	_
11-18	1897-1900	SCZ	_
11-19	1901-1905	risk	_
11-20	1906-1911	genes	_
11-21	1912-1916	into	_
11-22	1917-1927	biological	_
11-23	1928-1936	pathways	_
11-24	1937-1947	associated	_
11-25	1948-1952	with	_
11-26	1953-1965	intermediate	_
11-27	1966-1976	phenotypes	_
11-28	1977-1979	as	_
11-29	1980-1984	well	_
11-30	1985-1987	as	_
11-31	1988-1992	with	_
11-32	1993-2003	clinically	_
11-33	2004-2014	meaningful	_
11-34	2015-2026	information	_
11-35	2027-2028	.	_

Text=Materials and methods Participants Table 1 summarizes the demographic data of the subjects included in all experiments.
12-1	2029-2038	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	2039-2042	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	2043-2050	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	2051-2063	Participants	_
12-5	2064-2069	Table	_
12-6	2070-2071	1	_
12-7	2072-2082	summarizes	_
12-8	2083-2086	the	_
12-9	2087-2098	demographic	_
12-10	2099-2103	data	_
12-11	2104-2106	of	_
12-12	2107-2110	the	_
12-13	2111-2119	subjects	_
12-14	2120-2128	included	_
12-15	2129-2131	in	_
12-16	2132-2135	all	_
12-17	2136-2147	experiments	_
12-18	2148-2149	.	_

Text=After receiving a complete description of the study, all participants in the clinical and the imaging studies provided written informed consent following the guidelines of the Declaration of Helsinki.
13-1	2150-2155	After	_
13-2	2156-2165	receiving	_
13-3	2166-2167	a	_
13-4	2168-2176	complete	_
13-5	2177-2188	description	_
13-6	2189-2191	of	_
13-7	2192-2195	the	_
13-8	2196-2201	study	_
13-9	2202-2203	,	_
13-10	2204-2207	all	_
13-11	2208-2220	participants	_
13-12	2221-2223	in	_
13-13	2224-2227	the	_
13-14	2228-2236	clinical	_
13-15	2237-2240	and	_
13-16	2241-2244	the	_
13-17	2245-2252	imaging	_
13-18	2253-2260	studies	_
13-19	2261-2269	provided	_
13-20	2270-2277	written	_
13-21	2278-2286	informed	_
13-22	2287-2294	consent	_
13-23	2295-2304	following	_
13-24	2305-2308	the	_
13-25	2309-2319	guidelines	_
13-26	2320-2322	of	_
13-27	2323-2326	the	_
13-28	2327-2338	Declaration	_
13-29	2339-2341	of	_
13-30	2342-2350	Helsinki	_
13-31	2351-2352	.	_

Text=Protocols and procedures were approved by the ethics committee of the University of Bari and by the institutional review board of the National Institute of Health, Bethesda, MD, USA.
14-1	2353-2362	Protocols	_
14-2	2363-2366	and	_
14-3	2367-2377	procedures	_
14-4	2378-2382	were	_
14-5	2383-2391	approved	_
14-6	2392-2394	by	_
14-7	2395-2398	the	_
14-8	2399-2405	ethics	_
14-9	2406-2415	committee	_
14-10	2416-2418	of	_
14-11	2419-2422	the	_
14-12	2423-2433	University	_
14-13	2434-2436	of	_
14-14	2437-2441	Bari	_
14-15	2442-2445	and	_
14-16	2446-2448	by	_
14-17	2449-2452	the	_
14-18	2453-2466	institutional	_
14-19	2467-2473	review	_
14-20	2474-2479	board	_
14-21	2480-2482	of	_
14-22	2483-2486	the	_
14-23	2487-2495	National	_
14-24	2496-2505	Institute	_
14-25	2506-2508	of	_
14-26	2509-2515	Health	_
14-27	2516-2517	,	_
14-28	2518-2526	Bethesda	_
14-29	2527-2528	,	_
14-30	2529-2531	MD	_
14-31	2532-2533	,	_
14-32	2534-2537	USA	_
14-33	2538-2539	.	_

Text=Network identification We used the publicly available Braincloud data set (http: //braincloud.jhmi.edu/) for a genome-wide Weighted Genes Co-expression Network Analysis.
15-1	2540-2547	Network	_
15-2	2548-2562	identification	_
15-3	2563-2565	We	_
15-4	2566-2570	used	_
15-5	2571-2574	the	_
15-6	2575-2583	publicly	_
15-7	2584-2593	available	_
15-8	2594-2604	Braincloud	_
15-9	2605-2609	data	_
15-10	2610-2613	set	_
15-11	2614-2615	(	_
15-12	2616-2620	http	_
15-13	2621-2622	:	_
15-14	2623-2645	//braincloud.jhmi.edu/	_
15-15	2646-2647	)	_
15-16	2648-2651	for	_
15-17	2652-2653	a	_
15-18	2654-2665	genome-wide	_
15-19	2666-2674	Weighted	_
15-20	2675-2680	Genes	_
15-21	2681-2694	Co-expression	_
15-22	2695-2702	Network	_
15-23	2703-2711	Analysis	_
15-24	2712-2713	.	_

Text=The sample included 199 observations (demographics in Table 1).
16-1	2714-2717	The	_
16-2	2718-2724	sample	_
16-3	2725-2733	included	_
16-4	2734-2737	199	_
16-5	2738-2750	observations	_
16-6	2751-2752	(	_
16-7	2753-2765	demographics	_
16-8	2766-2768	in	_
16-9	2769-2774	Table	_
16-10	2775-2776	1	_
16-11	2777-2778	)	_
16-12	2779-2780	.	_

Text=We preprocessed the gene expression matrix to factor out confounding variables, including demographics.
17-1	2781-2783	We	_
17-2	2784-2796	preprocessed	_
17-3	2797-2800	the	_
17-4	2801-2805	gene	_
17-5	2806-2816	expression	_
17-6	2817-2823	matrix	_
17-7	2824-2826	to	_
17-8	2827-2833	factor	_
17-9	2834-2837	out	_
17-10	2838-2849	confounding	_
17-11	2850-2859	variables	_
17-12	2860-2861	,	_
17-13	2862-2871	including	_
17-14	2872-2884	demographics	_
17-15	2885-2886	.	_

Text=The first principal component of the DRD2 gene set (module eigengene, ME) served to track the simultaneous variation of the whole gene set.
18-1	2887-2890	The	_
18-2	2891-2896	first	_
18-3	2897-2906	principal	_
18-4	2907-2916	component	_
18-5	2917-2919	of	_
18-6	2920-2923	the	_
18-7	2924-2928	DRD2	_
18-8	2929-2933	gene	_
18-9	2934-2937	set	_
18-10	2938-2939	(	_
18-11	2940-2946	module	_
18-12	2947-2956	eigengene	_
18-13	2957-2958	,	_
18-14	2959-2961	ME	_
18-15	2962-2963	)	_
18-16	2964-2970	served	_
18-17	2971-2973	to	_
18-18	2974-2979	track	_
18-19	2980-2983	the	_
18-20	2984-2996	simultaneous	_
18-21	2997-3006	variation	_
18-22	3007-3009	of	_
18-23	3010-3013	the	_
18-24	3014-3019	whole	_
18-25	3020-3024	gene	_
18-26	3025-3028	set	_
18-27	3029-3030	.	_

Text=We correlated this co-expression measure with DRD2 expression levels.
19-1	3031-3033	We	_
19-2	3034-3044	correlated	_
19-3	3045-3049	this	_
19-4	3050-3063	co-expression	_
19-5	3064-3071	measure	_
19-6	3072-3076	with	_
19-7	3077-3081	DRD2	_
19-8	3082-3092	expression	_
19-9	3093-3099	levels	_
19-10	3100-3101	.	_

Text=To investigate the biological functions that may be subserved by this ensemble of co-expressed genes, we computed gene ontology enrichment analysis using AmiGO2 (http: //amigo.geneontology.org/amigo/landing).
20-1	3102-3104	To	_
20-2	3105-3116	investigate	_
20-3	3117-3120	the	_
20-4	3121-3131	biological	_
20-5	3132-3141	functions	_
20-6	3142-3146	that	_
20-7	3147-3150	may	_
20-8	3151-3153	be	_
20-9	3154-3163	subserved	_
20-10	3164-3166	by	_
20-11	3167-3171	this	_
20-12	3172-3180	ensemble	_
20-13	3181-3183	of	_
20-14	3184-3196	co-expressed	_
20-15	3197-3202	genes	_
20-16	3203-3204	,	_
20-17	3205-3207	we	_
20-18	3208-3216	computed	_
20-19	3217-3221	gene	_
20-20	3222-3230	ontology	_
20-21	3231-3241	enrichment	_
20-22	3242-3250	analysis	_
20-23	3251-3256	using	_
20-24	3257-3263	AmiGO2	_
20-25	3264-3265	(	_
20-26	3266-3270	http	_
20-27	3271-3272	:	_
20-28	3273-3311	//amigo.geneontology.org/amigo/landing	_
20-29	3312-3313	)	_
20-30	3314-3315	.	_

Text=Finally, we assessed enrichment of the gene set for the loci associated with SCZ risk by the Psychiatric Genomic Consortium (PGC with a hypergeometric test (SI Materials and Methods).
21-1	3316-3323	Finally	_
21-2	3324-3325	,	_
21-3	3326-3328	we	_
21-4	3329-3337	assessed	_
21-5	3338-3348	enrichment	_
21-6	3349-3351	of	_
21-7	3352-3355	the	_
21-8	3356-3360	gene	_
21-9	3361-3364	set	_
21-10	3365-3368	for	_
21-11	3369-3372	the	_
21-12	3373-3377	loci	_
21-13	3378-3388	associated	_
21-14	3389-3393	with	_
21-15	3394-3397	SCZ	_
21-16	3398-3402	risk	_
21-17	3403-3405	by	_
21-18	3406-3409	the	_
21-19	3410-3421	Psychiatric	_
21-20	3422-3429	Genomic	_
21-21	3430-3440	Consortium	_
21-22	3441-3442	(	_
21-23	3443-3446	PGC	_
21-24	3447-3451	with	_
21-25	3452-3453	a	_
21-26	3454-3468	hypergeometric	_
21-27	3469-3473	test	_
21-28	3474-3475	(	_
21-29	3476-3478	SI	_
21-30	3479-3488	Materials	_
21-31	3489-3492	and	_
21-32	3493-3500	Methods	_
21-33	3501-3502	)	_
21-34	3503-3504	.	_

Text=SNP association study We performed a gene set-wide association study of SNPs with the ME.
22-1	3505-3508	SNP	_
22-2	3509-3520	association	_
22-3	3521-3526	study	_
22-4	3527-3529	We	_
22-5	3530-3539	performed	_
22-6	3540-3541	a	_
22-7	3542-3546	gene	_
22-8	3547-3555	set-wide	_
22-9	3556-3567	association	_
22-10	3568-3573	study	_
22-11	3574-3576	of	_
22-12	3577-3581	SNPs	_
22-13	3582-3586	with	_
22-14	3587-3590	the	_
22-15	3591-3593	ME	_
22-16	3594-3595	.	_

Text=The sample size of our post-mortem data set is probably small for a genetic association study, and co-expression is most likely a phenotypic trait with complex heritability, much like SCZ.
23-1	3596-3599	The	_
23-2	3600-3606	sample	_
23-3	3607-3611	size	_
23-4	3612-3614	of	_
23-5	3615-3618	our	_
23-6	3619-3630	post-mortem	_
23-7	3631-3635	data	_
23-8	3636-3639	set	_
23-9	3640-3642	is	_
23-10	3643-3651	probably	_
23-11	3652-3657	small	_
23-12	3658-3661	for	_
23-13	3662-3663	a	_
23-14	3664-3671	genetic	_
23-15	3672-3683	association	_
23-16	3684-3689	study	_
23-17	3690-3691	,	_
23-18	3692-3695	and	_
23-19	3696-3709	co-expression	_
23-20	3710-3712	is	_
23-21	3713-3717	most	_
23-22	3718-3724	likely	_
23-23	3725-3726	a	_
23-24	3727-3737	phenotypic	_
23-25	3738-3743	trait	_
23-26	3744-3748	with	_
23-27	3749-3756	complex	_
23-28	3757-3769	heritability	_
23-29	3770-3771	,	_
23-30	3772-3776	much	_
23-31	3777-3781	like	_
23-32	3782-3785	SCZ	_
23-33	3786-3787	.	_

Text=Power calculations in genetic association studies have been shown to depend on many factors, including heritability of the trait, the proportion of variance explained by the genotyped SNPs, the total number of SNPs, the proportion of SNPs with no effect on the trait, the total sample size and the P-value threshold for SNP selection.
24-1	3788-3793	Power	_
24-2	3794-3806	calculations	_
24-3	3807-3809	in	_
24-4	3810-3817	genetic	_
24-5	3818-3829	association	_
24-6	3830-3837	studies	_
24-7	3838-3842	have	_
24-8	3843-3847	been	_
24-9	3848-3853	shown	_
24-10	3854-3856	to	_
24-11	3857-3863	depend	_
24-12	3864-3866	on	_
24-13	3867-3871	many	_
24-14	3872-3879	factors	_
24-15	3880-3881	,	_
24-16	3882-3891	including	_
24-17	3892-3904	heritability	_
24-18	3905-3907	of	_
24-19	3908-3911	the	_
24-20	3912-3917	trait	_
24-21	3918-3919	,	_
24-22	3920-3923	the	_
24-23	3924-3934	proportion	_
24-24	3935-3937	of	_
24-25	3938-3946	variance	_
24-26	3947-3956	explained	_
24-27	3957-3959	by	_
24-28	3960-3963	the	_
24-29	3964-3973	genotyped	_
24-30	3974-3978	SNPs	_
24-31	3979-3980	,	_
24-32	3981-3984	the	_
24-33	3985-3990	total	_
24-34	3991-3997	number	_
24-35	3998-4000	of	_
24-36	4001-4005	SNPs	_
24-37	4006-4007	,	_
24-38	4008-4011	the	_
24-39	4012-4022	proportion	_
24-40	4023-4025	of	_
24-41	4026-4030	SNPs	_
24-42	4031-4035	with	_
24-43	4036-4038	no	_
24-44	4039-4045	effect	_
24-45	4046-4048	on	_
24-46	4049-4052	the	_
24-47	4053-4058	trait	_
24-48	4059-4060	,	_
24-49	4061-4064	the	_
24-50	4065-4070	total	_
24-51	4071-4077	sample	_
24-52	4078-4082	size	_
24-53	4083-4086	and	_
24-54	4087-4090	the	_
24-55	4091-4098	P-value	_
24-56	4099-4108	threshold	_
24-57	4109-4112	for	_
24-58	4113-4116	SNP	_
24-59	4117-4126	selection	_
24-60	4127-4128	.	_

Text=The heritability of expression quantitative trait loci (eQTLs) is extremely variable and appears to be comparable between cis- and trans-eQTLs (co-eQTLs fall in the latter category).
25-1	4129-4132	The	_
25-2	4133-4145	heritability	_
25-3	4146-4148	of	_
25-4	4149-4159	expression	_
25-5	4160-4172	quantitative	_
25-6	4173-4178	trait	_
25-7	4179-4183	loci	_
25-8	4184-4185	(	_
25-9	4186-4191	eQTLs	_
25-10	4192-4193	)	_
25-11	4194-4196	is	_
25-12	4197-4206	extremely	_
25-13	4207-4215	variable	_
25-14	4216-4219	and	_
25-15	4220-4227	appears	_
25-16	4228-4230	to	_
25-17	4231-4233	be	_
25-18	4234-4244	comparable	_
25-19	4245-4252	between	_
25-20	4253-4257	cis-	_
25-21	4258-4261	and	_
25-22	4262-4273	trans-eQTLs	_
25-23	4274-4275	(	_
25-24	4276-4284	co-eQTLs	_
25-25	4285-4289	fall	_
25-26	4290-4292	in	_
25-27	4293-4296	the	_
25-28	4297-4303	latter	_
25-29	4304-4312	category	_
25-30	4313-4314	)	_
25-31	4315-4316	.	_

Text=Nevertheless, there is evidence of high replicability of eQTLs both with stringent and more lenient thresholds of significance.
26-1	4317-4329	Nevertheless	_
26-2	4330-4331	,	_
26-3	4332-4337	there	_
26-4	4338-4340	is	_
26-5	4341-4349	evidence	_
26-6	4350-4352	of	_
26-7	4353-4357	high	_
26-8	4358-4371	replicability	_
26-9	4372-4374	of	_
26-10	4375-4380	eQTLs	_
26-11	4381-4385	both	_
26-12	4386-4390	with	_
26-13	4391-4400	stringent	_
26-14	4401-4404	and	_
26-15	4405-4409	more	_
26-16	4410-4417	lenient	_
26-17	4418-4428	thresholds	_
26-18	4429-4431	of	_
26-19	4432-4444	significance	_
26-20	4445-4446	.	_

Text=These findings suggest that, beside statistical significance, genetic signals in the study of gene expression may be found beyond the threshold for corrected or nominal significance, as is also the case of complex clinical traits.
27-1	4447-4452	These	_
27-2	4453-4461	findings	_
27-3	4462-4469	suggest	_
27-4	4470-4474	that	_
27-5	4475-4476	,	_
27-6	4477-4483	beside	_
27-7	4484-4495	statistical	_
27-8	4496-4508	significance	_
27-9	4509-4510	,	_
27-10	4511-4518	genetic	_
27-11	4519-4526	signals	_
27-12	4527-4529	in	_
27-13	4530-4533	the	_
27-14	4534-4539	study	_
27-15	4540-4542	of	_
27-16	4543-4547	gene	_
27-17	4548-4558	expression	_
27-18	4559-4562	may	_
27-19	4563-4565	be	_
27-20	4566-4571	found	_
27-21	4572-4578	beyond	_
27-22	4579-4582	the	_
27-23	4583-4592	threshold	_
27-24	4593-4596	for	_
27-25	4597-4606	corrected	_
27-26	4607-4609	or	_
27-27	4610-4617	nominal	_
27-28	4618-4630	significance	_
27-29	4631-4632	,	_
27-30	4633-4635	as	_
27-31	4636-4638	is	_
27-32	4639-4643	also	_
27-33	4644-4647	the	_
27-34	4648-4652	case	_
27-35	4653-4655	of	_
27-36	4656-4663	complex	_
27-37	4664-4672	clinical	_
27-38	4673-4679	traits	_
27-39	4680-4681	.	_

Text=Based on these considerations, we first tested for co-eQTLs that would survive stringent Bonferroni correction; then, we employed more permissive statistics for our association to minimize false-negative findings and performed internal cross-validations and independent replication to minimize type I errors.
28-1	4682-4687	Based	_
28-2	4688-4690	on	_
28-3	4691-4696	these	_
28-4	4697-4711	considerations	_
28-5	4712-4713	,	_
28-6	4714-4716	we	_
28-7	4717-4722	first	_
28-8	4723-4729	tested	_
28-9	4730-4733	for	_
28-10	4734-4742	co-eQTLs	_
28-11	4743-4747	that	_
28-12	4748-4753	would	_
28-13	4754-4761	survive	_
28-14	4762-4771	stringent	_
28-15	4772-4782	Bonferroni	_
28-16	4783-4793	correction	_
28-17	4794-4795	;	_
28-18	4796-4800	then	_
28-19	4801-4802	,	_
28-20	4803-4805	we	_
28-21	4806-4814	employed	_
28-22	4815-4819	more	_
28-23	4820-4830	permissive	_
28-24	4831-4841	statistics	_
28-25	4842-4845	for	_
28-26	4846-4849	our	_
28-27	4850-4861	association	_
28-28	4862-4864	to	_
28-29	4865-4873	minimize	_
28-30	4874-4888	false-negative	_
28-31	4889-4897	findings	_
28-32	4898-4901	and	_
28-33	4902-4911	performed	_
28-34	4912-4920	internal	_
28-35	4921-4938	cross-validations	_
28-36	4939-4942	and	_
28-37	4943-4954	independent	_
28-38	4955-4966	replication	_
28-39	4967-4969	to	_
28-40	4970-4978	minimize	_
28-41	4979-4983	type	_
28-42	4984-4985	I	_
28-43	4986-4992	errors	_
28-44	4993-4994	.	_

Text=Through this procedure, we aimed at identifying an ensemble of SNPs that, together, predict co-expression.
29-1	4995-5002	Through	_
29-2	5003-5007	this	_
29-3	5008-5017	procedure	_
29-4	5018-5019	,	_
29-5	5020-5022	we	_
29-6	5023-5028	aimed	_
29-7	5029-5031	at	_
29-8	5032-5043	identifying	_
29-9	5044-5046	an	_
29-10	5047-5055	ensemble	_
29-11	5056-5058	of	_
29-12	5059-5063	SNPs	_
29-13	5064-5068	that	_
29-14	5069-5070	,	_
29-15	5071-5079	together	_
29-16	5080-5081	,	_
29-17	5082-5089	predict	_
29-18	5090-5103	co-expression	_
29-19	5104-5105	.	_

Text=We used eight SNPs associated with the first principal component of gene set co-expression with P <0.005 to compute the PCI.
30-1	5106-5108	We	_
30-2	5109-5113	used	_
30-3	5114-5119	eight	_
30-4	5120-5124	SNPs	_
30-5	5125-5135	associated	_
30-6	5136-5140	with	_
30-7	5141-5144	the	_
30-8	5145-5150	first	_
30-9	5151-5160	principal	_
30-10	5161-5170	component	_
30-11	5171-5173	of	_
30-12	5174-5178	gene	_
30-13	5179-5182	set	_
30-14	5183-5196	co-expression	_
30-15	5197-5201	with	_
30-16	5202-5203	P	_
30-17	5204-5205	<	_
30-18	5206-5211	0.005	_
30-19	5212-5214	to	_
30-20	5215-5222	compute	_
30-21	5223-5226	the	_
30-22	5227-5230	PCI	_
30-23	5231-5232	.	_

Text=As a common method to select SNPs for subsequent inclusion in polygenic scores consists in increasing the number of SNPs until the proportion of variance plateaus, we also tested whether such an approach selected the same set of eight SNPs with P <0.005 (SI Materials and Methods).
31-1	5233-5235	As	_
31-2	5236-5237	a	_
31-3	5238-5244	common	_
31-4	5245-5251	method	_
31-5	5252-5254	to	_
31-6	5255-5261	select	_
31-7	5262-5266	SNPs	_
31-8	5267-5270	for	_
31-9	5271-5281	subsequent	_
31-10	5282-5291	inclusion	_
31-11	5292-5294	in	_
31-12	5295-5304	polygenic	_
31-13	5305-5311	scores	_
31-14	5312-5320	consists	_
31-15	5321-5323	in	_
31-16	5324-5334	increasing	_
31-17	5335-5338	the	_
31-18	5339-5345	number	_
31-19	5346-5348	of	_
31-20	5349-5353	SNPs	_
31-21	5354-5359	until	_
31-22	5360-5363	the	_
31-23	5364-5374	proportion	_
31-24	5375-5377	of	_
31-25	5378-5386	variance	_
31-26	5387-5395	plateaus	_
31-27	5396-5397	,	_
31-28	5398-5400	we	_
31-29	5401-5405	also	_
31-30	5406-5412	tested	_
31-31	5413-5420	whether	_
31-32	5421-5425	such	_
31-33	5426-5428	an	_
31-34	5429-5437	approach	_
31-35	5438-5446	selected	_
31-36	5447-5450	the	_
31-37	5451-5455	same	_
31-38	5456-5459	set	_
31-39	5460-5462	of	_
31-40	5463-5468	eight	_
31-41	5469-5473	SNPs	_
31-42	5474-5478	with	_
31-43	5479-5480	P	_
31-44	5481-5482	<	_
31-45	5483-5488	0.005	_
31-46	5489-5490	(	_
31-47	5491-5493	SI	_
31-48	5494-5503	Materials	_
31-49	5504-5507	and	_
31-50	5508-5515	Methods	_
31-51	5516-5517	)	_
31-52	5518-5519	.	_

Text=We interrogated Haploreg v4.1 (http: //archive.broadinstitute.org/mammals/haploreg/haploreg.php) to gain information on the possible regulatory functions of these SNPs.
32-1	5520-5522	We	_
32-2	5523-5535	interrogated	_
32-3	5536-5544	Haploreg	_
32-4	5545-5549	v4.1	_
32-5	5550-5551	(	_
32-6	5552-5556	http	_
32-7	5557-5558	:	_
32-8	5559-5617	//archive.broadinstitute.org/mammals/haploreg/haploreg.php	_
32-9	5618-5619	)	_
32-10	5620-5622	to	_
32-11	5623-5627	gain	_
32-12	5628-5639	information	_
32-13	5640-5642	on	_
32-14	5643-5646	the	_
32-15	5647-5655	possible	_
32-16	5656-5666	regulatory	_
32-17	5667-5676	functions	_
32-18	5677-5679	of	_
32-19	5680-5685	these	_
32-20	5686-5690	SNPs	_
32-21	5691-5692	.	_

Text=Then, we computed the PCI by assigning a weight to each genotype of each SNP based on the expression profile within different genotypic groups.
33-1	5693-5697	Then	_
33-2	5698-5699	,	_
33-3	5700-5702	we	_
33-4	5703-5711	computed	_
33-5	5712-5715	the	_
33-6	5716-5719	PCI	_
33-7	5720-5722	by	_
33-8	5723-5732	assigning	_
33-9	5733-5734	a	_
33-10	5735-5741	weight	_
33-11	5742-5744	to	_
33-12	5745-5749	each	_
33-13	5750-5758	genotype	_
33-14	5759-5761	of	_
33-15	5762-5766	each	_
33-16	5767-5770	SNP	_
33-17	5771-5776	based	_
33-18	5777-5779	on	_
33-19	5780-5783	the	_
33-20	5784-5794	expression	_
33-21	5795-5802	profile	_
33-22	5803-5809	within	_
33-23	5810-5819	different	_
33-24	5820-5829	genotypic	_
33-25	5830-5836	groups	_
33-26	5837-5838	.	_

Text=The greater the PCI, the greater is the messenger RNA expression level of that individual.
34-1	5839-5842	The	_
34-2	5843-5850	greater	_
34-3	5851-5854	the	_
34-4	5855-5858	PCI	_
34-5	5859-5860	,	_
34-6	5861-5864	the	_
34-7	5865-5872	greater	_
34-8	5873-5875	is	_
34-9	5876-5879	the	_
34-10	5880-5889	messenger	_
34-11	5890-5893	RNA	_
34-12	5894-5904	expression	_
34-13	5905-5910	level	_
34-14	5911-5913	of	_
34-15	5914-5918	that	_
34-16	5919-5929	individual	_
34-17	5930-5931	.	_

Text=We cross-validated the PCI and assessed ethnicity and population stratification effects, as well as age effects (SI Materials and Methods).
35-1	5932-5934	We	_
35-2	5935-5950	cross-validated	_
35-3	5951-5954	the	_
35-4	5955-5958	PCI	_
35-5	5959-5962	and	_
35-6	5963-5971	assessed	_
35-7	5972-5981	ethnicity	_
35-8	5982-5985	and	_
35-9	5986-5996	population	_
35-10	5997-6011	stratification	_
35-11	6012-6019	effects	_
35-12	6020-6021	,	_
35-13	6022-6024	as	_
35-14	6025-6029	well	_
35-15	6030-6032	as	_
35-16	6033-6036	age	_
35-17	6037-6044	effects	_
35-18	6045-6046	(	_
35-19	6047-6049	SI	_
35-20	6050-6059	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
35-21	6060-6063	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
35-22	6064-6071	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
35-23	6072-6073	)	_
35-24	6074-6075	.	_

Text=We used the publicly available BrainEAC data set to replicate the association of the PCI with D2L co-expression in the frontal cortex.
36-1	6076-6078	We	_
36-2	6079-6083	used	_
36-3	6084-6087	the	_
36-4	6088-6096	publicly	_
36-5	6097-6106	available	_
36-6	6107-6115	BrainEAC	_
36-7	6116-6120	data	_
36-8	6121-6124	set	_
36-9	6125-6127	to	_
36-10	6128-6137	replicate	_
36-11	6138-6141	the	_
36-12	6142-6153	association	_
36-13	6154-6156	of	_
36-14	6157-6160	the	_
36-15	6161-6164	PCI	_
36-16	6165-6169	with	_
36-17	6170-6173	D2L	_
36-18	6174-6187	co-expression	_
36-19	6188-6190	in	_
36-20	6191-6194	the	_
36-21	6195-6202	frontal	_
36-22	6203-6209	cortex	_
36-23	6210-6211	.	_

Text=From this data set, we selected the probes of all genes included in the D2L co-expression pathway and preprocessed the data as above reported.
37-1	6212-6216	From	_
37-2	6217-6221	this	_
37-3	6222-6226	data	_
37-4	6227-6230	set	_
37-5	6231-6232	,	_
37-6	6233-6235	we	_
37-7	6236-6244	selected	_
37-8	6245-6248	the	_
37-9	6249-6255	probes	_
37-10	6256-6258	of	_
37-11	6259-6262	all	_
37-12	6263-6268	genes	_
37-13	6269-6277	included	_
37-14	6278-6280	in	_
37-15	6281-6284	the	_
37-16	6285-6288	D2L	_
37-17	6289-6302	co-expression	_
37-18	6303-6310	pathway	_
37-19	6311-6314	and	_
37-20	6315-6327	preprocessed	_
37-21	6328-6331	the	_
37-22	6332-6336	data	_
37-23	6337-6339	as	_
37-24	6340-6345	above	_
37-25	6346-6354	reported	_
37-26	6355-6356	.	_

Text=The sample included 50 Caucasian participants.
38-1	6357-6360	The	_
38-2	6361-6367	sample	_
38-3	6368-6376	included	_
38-4	6377-6379	50	_
38-5	6380-6389	Caucasian	_
38-6	6390-6402	participants	_
38-7	6403-6404	.	_

Text=We computed the PCI of each individual and associated it with the ME using Pearson ’ s correlation.
39-1	6405-6407	We	_
39-2	6408-6416	computed	_
39-3	6417-6420	the	_
39-4	6421-6424	PCI	_
39-5	6425-6427	of	_
39-6	6428-6432	each	_
39-7	6433-6443	individual	_
39-8	6444-6447	and	_
39-9	6448-6458	associated	_
39-10	6459-6461	it	_
39-11	6462-6466	with	_
39-12	6467-6470	the	_
39-13	6471-6473	ME	_
39-14	6474-6479	using	_
39-15	6480-6487	Pearson	_
39-16	6488-6489	’	_
39-17	6490-6491	s	_
39-18	6492-6503	correlation	_
39-19	6504-6505	.	_

Text=Imaging study We recruited 124 healthy unrelated Caucasian adults from the region of Apulia, Italy (demographics in Table 1), for a functional magnetic resonance imaging (fMRI) experiment and genotyped them for the SNPs included in the PCI.
40-1	6506-6513	Imaging	_
40-2	6514-6519	study	_
40-3	6520-6522	We	_
40-4	6523-6532	recruited	_
40-5	6533-6536	124	_
40-6	6537-6544	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-7	6545-6554	unrelated	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-8	6555-6564	Caucasian	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-9	6565-6571	adults	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
40-10	6572-6576	from	_
40-11	6577-6580	the	_
40-12	6581-6587	region	_
40-13	6588-6590	of	_
40-14	6591-6597	Apulia	_
40-15	6598-6599	,	_
40-16	6600-6605	Italy	_
40-17	6606-6607	(	_
40-18	6608-6620	demographics	_
40-19	6621-6623	in	_
40-20	6624-6629	Table	_
40-21	6630-6631	1	_
40-22	6632-6633	)	_
40-23	6634-6635	,	_
40-24	6636-6639	for	_
40-25	6640-6641	a	_
40-26	6642-6652	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-27	6653-6661	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-28	6662-6671	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-29	6672-6679	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-30	6680-6681	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-31	6682-6686	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-32	6687-6688	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-33	6689-6699	experiment	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-34	6700-6703	and	_
40-35	6704-6713	genotyped	_
40-36	6714-6718	them	_
40-37	6719-6722	for	_
40-38	6723-6726	the	_
40-39	6727-6731	SNPs	_
40-40	6732-6740	included	_
40-41	6741-6743	in	_
40-42	6744-6747	the	_
40-43	6748-6751	PCI	_
40-44	6752-6753	.	_

Text=We used the n-back task to probe WM.
41-1	6754-6756	We	_
41-2	6757-6761	used	_
41-3	6762-6765	the	_
41-4	6766-6772	n-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-5	6773-6777	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
41-6	6778-6780	to	_
41-7	6781-6786	probe	_
41-8	6787-6789	WM	_
41-9	6790-6791	.	_

Text=Stimuli consisted of numbers (1–4) shown in random sequence and displayed at the points of a diamond-shaped box.
42-1	6792-6799	Stimuli	_
42-2	6800-6809	consisted	_
42-3	6810-6812	of	_
42-4	6813-6820	numbers	_
42-5	6821-6822	(	_
42-6	6823-6826	1–4	_
42-7	6827-6828	)	_
42-8	6829-6834	shown	_
42-9	6835-6837	in	_
42-10	6838-6844	random	_
42-11	6845-6853	sequence	_
42-12	6854-6857	and	_
42-13	6858-6867	displayed	_
42-14	6868-6870	at	_
42-15	6871-6874	the	_
42-16	6875-6881	points	_
42-17	6882-6884	of	_
42-18	6885-6886	a	_
42-19	6887-6901	diamond-shaped	_
42-20	6902-6905	box	_
42-21	6906-6907	.	_

Text=There was a non-memory-guided control condition (0-back) that required subjects to identify the stimulus currently seen.
43-1	6908-6913	There	_
43-2	6914-6917	was	_
43-3	6918-6919	a	_
43-4	6920-6937	non-memory-guided	_
43-5	6938-6945	control	_
43-6	6946-6955	condition	_
43-7	6956-6957	(	_
43-8	6958-6964	0-back	_
43-9	6965-6966	)	_
43-10	6967-6971	that	_
43-11	6972-6980	required	_
43-12	6981-6989	subjects	_
43-13	6990-6992	to	_
43-14	6993-7001	identify	_
43-15	7002-7005	the	_
43-16	7006-7014	stimulus	_
43-17	7015-7024	currently	_
43-18	7025-7029	seen	_
43-19	7030-7031	.	_

Text=As memory load increased, the task required the recollection of a stimulus seen one (1-back) or two (2-back) stimuli before, while keeping on encoding incoming stimuli (SI Materials and Methods).
44-1	7032-7034	As	_
44-2	7035-7041	memory	_
44-3	7042-7046	load	_
44-4	7047-7056	increased	_
44-5	7057-7058	,	_
44-6	7059-7062	the	_
44-7	7063-7067	task	_
44-8	7068-7076	required	_
44-9	7077-7080	the	_
44-10	7081-7093	recollection	_
44-11	7094-7096	of	_
44-12	7097-7098	a	_
44-13	7099-7107	stimulus	_
44-14	7108-7112	seen	_
44-15	7113-7116	one	_
44-16	7117-7118	(	_
44-17	7119-7125	1-back	_
44-18	7126-7127	)	_
44-19	7128-7130	or	_
44-20	7131-7134	two	_
44-21	7135-7136	(	_
44-22	7137-7143	2-back	_
44-23	7144-7145	)	_
44-24	7146-7153	stimuli	_
44-25	7154-7160	before	_
44-26	7161-7162	,	_
44-27	7163-7168	while	_
44-28	7169-7176	keeping	_
44-29	7177-7179	on	_
44-30	7180-7188	encoding	_
44-31	7189-7197	incoming	_
44-32	7198-7205	stimuli	_
44-33	7206-7207	(	_
44-34	7208-7210	SI	_
44-35	7211-7220	Materials	_
44-36	7221-7224	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
44-37	7225-7232	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
44-38	7233-7234	)	_
44-39	7235-7236	.	_

Text=We tested the association of the PCI with brain activation using repeated measures analysis of covariance (within-subject factor: LOAD (1-back, 2-back); covariates: age, gender and handedness; whole-brain topological false discovery rate-corrected α=0.05; extent threshold=6, that is,> 300 mm3).
45-1	7237-7239	We	_
45-2	7240-7246	tested	_
45-3	7247-7250	the	_
45-4	7251-7262	association	_
45-5	7263-7265	of	_
45-6	7266-7269	the	_
45-7	7270-7273	PCI	_
45-8	7274-7278	with	_
45-9	7279-7284	brain	_
45-10	7285-7295	activation	_
45-11	7296-7301	using	_
45-12	7302-7310	repeated	_
45-13	7311-7319	measures	_
45-14	7320-7328	analysis	_
45-15	7329-7331	of	_
45-16	7332-7342	covariance	_
45-17	7343-7344	(	_
45-18	7345-7359	within-subject	_
45-19	7360-7366	factor	_
45-20	7367-7368	:	_
45-21	7369-7373	LOAD	_
45-22	7374-7375	(	_
45-23	7376-7382	1-back	_
45-24	7383-7384	,	_
45-25	7385-7391	2-back	_
45-26	7392-7393	)	_
45-27	7394-7395	;	_
45-28	7396-7406	covariates	_
45-29	7407-7408	:	_
45-30	7409-7412	age	_
45-31	7413-7414	,	_
45-32	7415-7421	gender	_
45-33	7422-7425	and	_
45-34	7426-7436	handedness	_
45-35	7437-7438	;	_
45-36	7439-7450	whole-brain	_
45-37	7451-7462	topological	_
45-38	7463-7468	false	_
45-39	7469-7478	discovery	_
45-40	7479-7493	rate-corrected	_
45-41	7494-7500	α=0.05	_
45-42	7501-7502	;	_
45-43	7503-7509	extent	_
45-44	7510-7521	threshold=6	_
45-45	7522-7523	,	_
45-46	7524-7528	that	_
45-47	7529-7531	is	_
45-48	7532-7533	,	_
45-49	7534-7535	>	_
45-50	7536-7539	300	_
45-51	7540-7543	mm3	_
45-52	7544-7545	)	_
45-53	7546-7547	.	_

Text=We recruited a second fMRI sample of 244 Caucasian healthy volunteers as part of the NIMH Clinical Brain Disorders Branch ‘ Sibling Study ’ (Table 1).
46-1	7548-7550	We	_
46-2	7551-7560	recruited	_
46-3	7561-7562	a	_
46-4	7563-7569	second	_
46-5	7570-7574	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
46-6	7575-7581	sample	_
46-7	7582-7584	of	_
46-8	7585-7588	244	_
46-9	7589-7598	Caucasian	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
46-10	7599-7606	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
46-11	7607-7617	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
46-12	7618-7620	as	_
46-13	7621-7625	part	_
46-14	7626-7628	of	_
46-15	7629-7632	the	_
46-16	7633-7637	NIMH	_
46-17	7638-7646	Clinical	_
46-18	7647-7652	Brain	_
46-19	7653-7662	Disorders	_
46-20	7663-7669	Branch	_
46-21	7670-7671	‘	_
46-22	7672-7679	Sibling	_
46-23	7680-7685	Study	_
46-24	7686-7687	’	_
46-25	7688-7689	(	_
46-26	7690-7695	Table	_
46-27	7696-7697	1	_
46-28	7698-7699	)	_
46-29	7700-7701	.	_

Text=These participants performed the same 2-back fMRI task described above and were genome-wide genotyped (SI Materials and Methods).
47-1	7702-7707	These	_
47-2	7708-7720	participants	_
47-3	7721-7730	performed	_
47-4	7731-7734	the	_
47-5	7735-7739	same	_
47-6	7740-7746	2-back	_
47-7	7747-7751	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
47-8	7752-7756	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
47-9	7757-7766	described	_
47-10	7767-7772	above	_
47-11	7773-7776	and	_
47-12	7777-7781	were	_
47-13	7782-7793	genome-wide	_
47-14	7794-7803	genotyped	_
47-15	7804-7805	(	_
47-16	7806-7808	SI	_
47-17	7809-7818	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
47-18	7819-7822	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
47-19	7823-7830	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
47-20	7831-7832	)	_
47-21	7833-7834	.	_

Text=The effect of the PCI on BOLD response was tested using robust linear models with age, gender and handedness as covariates of no interest.
48-1	7835-7838	The	_
48-2	7839-7845	effect	_
48-3	7846-7848	of	_
48-4	7849-7852	the	_
48-5	7853-7856	PCI	_
48-6	7857-7859	on	_
48-7	7860-7864	BOLD	_
48-8	7865-7873	response	_
48-9	7874-7877	was	_
48-10	7878-7884	tested	_
48-11	7885-7890	using	_
48-12	7891-7897	robust	_
48-13	7898-7904	linear	_
48-14	7905-7911	models	_
48-15	7912-7916	with	_
48-16	7917-7920	age	_
48-17	7921-7922	,	_
48-18	7923-7929	gender	_
48-19	7930-7933	and	_
48-20	7934-7944	handedness	_
48-21	7945-7947	as	_
48-22	7948-7958	covariates	_
48-23	7959-7961	of	_
48-24	7962-7964	no	_
48-25	7965-7973	interest	_
48-26	7974-7975	.	_

Text=We performed one-tailed t-tests using as regions of interest the clusters associated with the PCI in the first healthy sample.
49-1	7976-7978	We	_
49-2	7979-7988	performed	_
49-3	7989-7999	one-tailed	_
49-4	8000-8007	t-tests	_
49-5	8008-8013	using	_
49-6	8014-8016	as	_
49-7	8017-8024	regions	_
49-8	8025-8027	of	_
49-9	8028-8036	interest	_
49-10	8037-8040	the	_
49-11	8041-8049	clusters	_
49-12	8050-8060	associated	_
49-13	8061-8065	with	_
49-14	8066-8069	the	_
49-15	8070-8073	PCI	_
49-16	8074-8076	in	_
49-17	8077-8080	the	_
49-18	8081-8086	first	_
49-19	8087-8094	healthy	_
49-20	8095-8101	sample	_
49-21	8102-8103	.	_

Text=We used MarsBar (http: //marsbar.sourceforge.net/) to extract the percent signal change and corrected for the number of tests (false discovery rate).
50-1	8104-8106	We	_
50-2	8107-8111	used	_
50-3	8112-8119	MarsBar	_
50-4	8120-8121	(	_
50-5	8122-8126	http	_
50-6	8127-8128	:	_
50-7	8129-8155	//marsbar.sourceforge.net/	_
50-8	8156-8157	)	_
50-9	8158-8160	to	_
50-10	8161-8168	extract	_
50-11	8169-8172	the	_
50-12	8173-8180	percent	_
50-13	8181-8187	signal	_
50-14	8188-8194	change	_
50-15	8195-8198	and	_
50-16	8199-8208	corrected	_
50-17	8209-8212	for	_
50-18	8213-8216	the	_
50-19	8217-8223	number	_
50-20	8224-8226	of	_
50-21	8227-8232	tests	_
50-22	8233-8234	(	_
50-23	8235-8240	false	_
50-24	8241-8250	discovery	_
50-25	8251-8255	rate	_
50-26	8256-8257	)	_
50-27	8258-8259	.	_

Text=For the fMRI study on the clinical cohort, we recruited 29 Caucasian patients with SCID diagnosis of SCZ from the region of Apulia, Italy (Table 1).
51-1	8260-8263	For	_
51-2	8264-8267	the	_
51-3	8268-8272	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
51-4	8273-8278	study	_
51-5	8279-8281	on	_
51-6	8282-8285	the	_
51-7	8286-8294	clinical	_
51-8	8295-8301	cohort	_
51-9	8302-8303	,	_
51-10	8304-8306	we	_
51-11	8307-8316	recruited	_
51-12	8317-8319	29	_
51-13	8320-8329	Caucasian	_
51-14	8330-8338	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
51-15	8339-8343	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
51-16	8344-8348	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
51-17	8349-8358	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
51-18	8359-8361	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
51-19	8362-8365	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
51-20	8366-8370	from	_
51-21	8371-8374	the	_
51-22	8375-8381	region	_
51-23	8382-8384	of	_
51-24	8385-8391	Apulia	_
51-25	8392-8393	,	_
51-26	8394-8399	Italy	_
51-27	8400-8401	(	_
51-28	8402-8407	Table	_
51-29	8408-8409	1	_
51-30	8410-8411	)	_
51-31	8412-8413	.	_

Text=Genotyping and fMRI protocols matched the procedures followed for the first fMRI healthy sample.
52-1	8414-8424	Genotyping	_
52-2	8425-8428	and	_
52-3	8429-8433	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-4	8434-8443	protocols	_
52-5	8444-8451	matched	_
52-6	8452-8455	the	_
52-7	8456-8466	procedures	_
52-8	8467-8475	followed	_
52-9	8476-8479	for	_
52-10	8480-8483	the	_
52-11	8484-8489	first	_
52-12	8490-8494	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
52-13	8495-8502	healthy	_
52-14	8503-8509	sample	_
52-15	8510-8511	.	_

Text=Behavioral analyses In the first healthy fMRI sample, we investigated behavioral performance (accuracy and reaction time) during the WM task in the scanning session (SI Materials and Methods).
53-1	8512-8522	Behavioral	_
53-2	8523-8531	analyses	_
53-3	8532-8534	In	_
53-4	8535-8538	the	_
53-5	8539-8544	first	_
53-6	8545-8552	healthy	_
53-7	8553-8557	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
53-8	8558-8564	sample	_
53-9	8565-8566	,	_
53-10	8567-8569	we	_
53-11	8570-8582	investigated	_
53-12	8583-8593	behavioral	_
53-13	8594-8605	performance	_
53-14	8606-8607	(	_
53-15	8608-8616	accuracy	_
53-16	8617-8620	and	_
53-17	8621-8629	reaction	_
53-18	8630-8634	time	_
53-19	8635-8636	)	_
53-20	8637-8643	during	_
53-21	8644-8647	the	_
53-22	8648-8650	WM	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
53-23	8651-8655	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
53-24	8656-8658	in	_
53-25	8659-8662	the	_
53-26	8663-8671	scanning	_
53-27	8672-8679	session	_
53-28	8680-8681	(	_
53-29	8682-8684	SI	_
53-30	8685-8694	Materials	_
53-31	8695-8698	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
53-32	8699-8706	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
53-33	8707-8708	)	_
53-34	8709-8710	.	_

Text=We analyzed accuracy, that is, percent of correct responses, and reaction times with repeated measures analysis of covariance (within-subject factor: LOAD (1-back, 2-back)) and PCI as a predictor.
54-1	8711-8713	We	_
54-2	8714-8722	analyzed	_
54-3	8723-8731	accuracy	_
54-4	8732-8733	,	_
54-5	8734-8738	that	_
54-6	8739-8741	is	_
54-7	8742-8743	,	_
54-8	8744-8751	percent	_
54-9	8752-8754	of	_
54-10	8755-8762	correct	_
54-11	8763-8772	responses	_
54-12	8773-8774	,	_
54-13	8775-8778	and	_
54-14	8779-8787	reaction	_
54-15	8788-8793	times	_
54-16	8794-8798	with	_
54-17	8799-8807	repeated	_
54-18	8808-8816	measures	_
54-19	8817-8825	analysis	_
54-20	8826-8828	of	_
54-21	8829-8839	covariance	_
54-22	8840-8841	(	_
54-23	8842-8856	within-subject	_
54-24	8857-8863	factor	_
54-25	8864-8865	:	_
54-26	8866-8870	LOAD	_
54-27	8871-8872	(	_
54-28	8873-8879	1-back	_
54-29	8880-8881	,	_
54-30	8882-8888	2-back	_
54-31	8889-8890	)	_
54-32	8891-8892	)	_
54-33	8893-8896	and	_
54-34	8897-8900	PCI	_
54-35	8901-8903	as	_
54-36	8904-8905	a	_
54-37	8906-8915	predictor	_
54-38	8916-8917	.	_

Text=As we were testing two measures, we set the threshold for significance at α=0.025 (Bonferroni correction).
55-1	8918-8920	As	_
55-2	8921-8923	we	_
55-3	8924-8928	were	_
55-4	8929-8936	testing	_
55-5	8937-8940	two	_
55-6	8941-8949	measures	_
55-7	8950-8951	,	_
55-8	8952-8954	we	_
55-9	8955-8958	set	_
55-10	8959-8962	the	_
55-11	8963-8972	threshold	_
55-12	8973-8976	for	_
55-13	8977-8989	significance	_
55-14	8990-8992	at	_
55-15	8993-9000	α=0.025	_
55-16	9001-9002	(	_
55-17	9003-9013	Bonferroni	_
55-18	9014-9024	correction	_
55-19	9025-9026	)	_
55-20	9027-9028	.	_

Text=In the clinical fMRI sample, we analyzed behavioral performance following the same procedures employed for the first fMRI sample.
56-1	9029-9031	In	_
56-2	9032-9035	the	_
56-3	9036-9044	clinical	_
56-4	9045-9049	fMRI	_
56-5	9050-9056	sample	_
56-6	9057-9058	,	_
56-7	9059-9061	we	_
56-8	9062-9070	analyzed	_
56-9	9071-9081	behavioral	_
56-10	9082-9093	performance	_
56-11	9094-9103	following	_
56-12	9104-9107	the	_
56-13	9108-9112	same	_
56-14	9113-9123	procedures	_
56-15	9124-9132	employed	_
56-16	9133-9136	for	_
56-17	9137-9140	the	_
56-18	9141-9146	first	_
56-19	9147-9151	fMRI	_
56-20	9152-9158	sample	_
56-21	9159-9160	.	_

Text=Pharmacogenetics The first clinical cohort in the pharmacogenetic study included 47 Caucasian patients with SCZ (Structured Clinical Interview for DSM (SCID) diagnosis) recruited from the region of Apulia, Italy (Table 1).
57-1	9161-9177	Pharmacogenetics	_
57-2	9178-9181	The	_
57-3	9182-9187	first	_
57-4	9188-9196	clinical	_
57-5	9197-9203	cohort	_
57-6	9204-9206	in	_
57-7	9207-9210	the	_
57-8	9211-9226	pharmacogenetic	_
57-9	9227-9232	study	_
57-10	9233-9241	included	_
57-11	9242-9244	47	_
57-12	9245-9254	Caucasian	http://maven.renci.org/NeuroBridge/neurobridge#Education
57-13	9255-9263	patients	http://maven.renci.org/NeuroBridge/neurobridge#Education
57-14	9264-9268	with	http://maven.renci.org/NeuroBridge/neurobridge#Education
57-15	9269-9272	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Education
57-16	9273-9274	(	http://maven.renci.org/NeuroBridge/neurobridge#Education
57-17	9275-9285	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
57-18	9286-9294	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
57-19	9295-9304	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
57-20	9305-9308	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
57-21	9309-9312	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
57-22	9313-9314	(	_
57-23	9315-9319	SCID	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
57-24	9320-9321	)	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
57-25	9322-9331	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
57-26	9332-9333	)	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
57-27	9334-9343	recruited	_
57-28	9344-9348	from	_
57-29	9349-9352	the	_
57-30	9353-9359	region	_
57-31	9360-9362	of	_
57-32	9363-9369	Apulia	_
57-33	9370-9371	,	_
57-34	9372-9377	Italy	_
57-35	9378-9379	(	_
57-36	9380-9385	Table	_
57-37	9386-9387	1	_
57-38	9388-9389	)	_
57-39	9390-9391	.	_

Text=Treatment response was computed as the difference in the total Positive And Negative Syndrome Scale (PANSS) core between baseline and treatment end.
58-1	9392-9401	Treatment	_
58-2	9402-9410	response	_
58-3	9411-9414	was	_
58-4	9415-9423	computed	_
58-5	9424-9426	as	_
58-6	9427-9430	the	_
58-7	9431-9441	difference	_
58-8	9442-9444	in	_
58-9	9445-9448	the	_
58-10	9449-9454	total	_
58-11	9455-9463	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-12	9464-9467	And	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-13	9468-9476	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-14	9477-9485	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-15	9486-9491	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-16	9492-9493	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-17	9494-9499	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-18	9500-9501	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
58-19	9502-9506	core	_
58-20	9507-9514	between	_
58-21	9515-9523	baseline	_
58-22	9524-9527	and	_
58-23	9528-9537	treatment	_
58-24	9538-9541	end	_
58-25	9542-9543	.	_

Text=The second cohort consisted of 40 patients with SCZ with history of inadequate treatment response recruited at the Clinical Brain Disorders Branch SCZ inpatient research unit at the National Institutes of Health Clinical Center, Bethesda, MD, USA.
59-1	9544-9547	The	_
59-2	9548-9554	second	_
59-3	9555-9561	cohort	_
59-4	9562-9571	consisted	_
59-5	9572-9574	of	_
59-6	9575-9577	40	_
59-7	9578-9586	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-8	9587-9591	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-9	9592-9595	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-10	9596-9600	with	_
59-11	9601-9608	history	_
59-12	9609-9611	of	_
59-13	9612-9622	inadequate	_
59-14	9623-9632	treatment	_
59-15	9633-9641	response	_
59-16	9642-9651	recruited	_
59-17	9652-9654	at	_
59-18	9655-9658	the	_
59-19	9659-9667	Clinical	_
59-20	9668-9673	Brain	_
59-21	9674-9683	Disorders	_
59-22	9684-9690	Branch	_
59-23	9691-9694	SCZ	_
59-24	9695-9704	inpatient	_
59-25	9705-9713	research	_
59-26	9714-9718	unit	_
59-27	9719-9721	at	_
59-28	9722-9725	the	_
59-29	9726-9734	National	_
59-30	9735-9745	Institutes	_
59-31	9746-9748	of	_
59-32	9749-9755	Health	_
59-33	9756-9764	Clinical	_
59-34	9765-9771	Center	_
59-35	9772-9773	,	_
59-36	9774-9782	Bethesda	_
59-37	9783-9784	,	_
59-38	9785-9787	MD	_
59-39	9788-9789	,	_
59-40	9790-9793	USA	_
59-41	9794-9795	.	_

Text=Treatment response was defined as the difference between symptoms severity at the end of placebo treatment and severity at the end of drug treatment.
60-1	9796-9805	Treatment	_
60-2	9806-9814	response	_
60-3	9815-9818	was	_
60-4	9819-9826	defined	_
60-5	9827-9829	as	_
60-6	9830-9833	the	_
60-7	9834-9844	difference	_
60-8	9845-9852	between	_
60-9	9853-9861	symptoms	_
60-10	9862-9870	severity	_
60-11	9871-9873	at	_
60-12	9874-9877	the	_
60-13	9878-9881	end	_
60-14	9882-9884	of	_
60-15	9885-9892	placebo	_
60-16	9893-9902	treatment	_
60-17	9903-9906	and	_
60-18	9907-9915	severity	_
60-19	9916-9918	at	_
60-20	9919-9922	the	_
60-21	9923-9926	end	_
60-22	9927-9929	of	_
60-23	9930-9934	drug	_
60-24	9935-9944	treatment	_
60-25	9945-9946	.	_

Text=The clinical protocols used in the pharmacogenetic study for both samples have been described in detail previously (see Supplementary Table 2 for clinical data).
61-1	9947-9950	The	_
61-2	9951-9959	clinical	_
61-3	9960-9969	protocols	_
61-4	9970-9974	used	_
61-5	9975-9977	in	_
61-6	9978-9981	the	_
61-7	9982-9997	pharmacogenetic	_
61-8	9998-10003	study	_
61-9	10004-10007	for	_
61-10	10008-10012	both	_
61-11	10013-10020	samples	_
61-12	10021-10025	have	_
61-13	10026-10030	been	_
61-14	10031-10040	described	_
61-15	10041-10043	in	_
61-16	10044-10050	detail	_
61-17	10051-10061	previously	_
61-18	10062-10063	(	_
61-19	10064-10067	see	_
61-20	10068-10081	Supplementary	_
61-21	10082-10087	Table	_
61-22	10088-10089	2	_
61-23	10090-10093	for	_
61-24	10094-10102	clinical	_
61-25	10103-10107	data	_
61-26	10108-10109	)	_
61-27	10110-10111	.	_

Text=We first performed an association study to investigate the direction of the PCI treatment response relationship using Spearman ’ s Rho; then, we assessed the potency of the PCI as predictor of treatment response in comparison with pharmacological doses and off-medication symptom severity using Receiver Operating Characteristic curves (SI Materials and Methods).
62-1	10112-10114	We	_
62-2	10115-10120	first	_
62-3	10121-10130	performed	_
62-4	10131-10133	an	_
62-5	10134-10145	association	_
62-6	10146-10151	study	_
62-7	10152-10154	to	_
62-8	10155-10166	investigate	_
62-9	10167-10170	the	_
62-10	10171-10180	direction	_
62-11	10181-10183	of	_
62-12	10184-10187	the	_
62-13	10188-10191	PCI	_
62-14	10192-10201	treatment	_
62-15	10202-10210	response	_
62-16	10211-10223	relationship	_
62-17	10224-10229	using	_
62-18	10230-10238	Spearman	_
62-19	10239-10240	’	_
62-20	10241-10242	s	_
62-21	10243-10246	Rho	_
62-22	10247-10248	;	_
62-23	10249-10253	then	_
62-24	10254-10255	,	_
62-25	10256-10258	we	_
62-26	10259-10267	assessed	_
62-27	10268-10271	the	_
62-28	10272-10279	potency	_
62-29	10280-10282	of	_
62-30	10283-10286	the	_
62-31	10287-10290	PCI	_
62-32	10291-10293	as	_
62-33	10294-10303	predictor	_
62-34	10304-10306	of	_
62-35	10307-10316	treatment	_
62-36	10317-10325	response	_
62-37	10326-10328	in	_
62-38	10329-10339	comparison	_
62-39	10340-10344	with	_
62-40	10345-10360	pharmacological	_
62-41	10361-10366	doses	_
62-42	10367-10370	and	_
62-43	10371-10385	off-medication	_
62-44	10386-10393	symptom	_
62-45	10394-10402	severity	_
62-46	10403-10408	using	_
62-47	10409-10417	Receiver	_
62-48	10418-10427	Operating	_
62-49	10428-10442	Characteristic	_
62-50	10443-10449	curves	_
62-51	10450-10451	(	_
62-52	10452-10454	SI	_
62-53	10455-10464	Materials	_
62-54	10465-10468	and	_
62-55	10469-10476	Methods	_
62-56	10477-10478	)	_
62-57	10479-10480	.	_

